Plus   Neg

Ligand Pharmaceuticals (LGND) Is Up Sharply Following FDA Approval

Ligand Pharmaceuticals (LGND) partner GlaxoSmithKline (GSK) announced Monday morning that the FDA approved PROMACTA for the treatment of thrombocytopenia in patients with chronic hepatitis C.

Ligand Pharmaceuticals has spiked to the upside following a slightly delayed opening and is currently higher by 2.61 at $19.28. The stock is now challenging the highs of the year, trading at a 3-month high.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT